Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the major contributor to the global burden of chronic liver diseases and ranges from simple and reversible steatosis to nonalcoholic steatohepatitis (NASH), which may progress into cirrhosis and hepatocellular carcinoma (HCC). HCC represents the most common liver cancer, and it is a leading cause of death worldwide with an increasing trend for the future. Due to late diagnosis, non-responsiveness to systemic therapy, and high cancer heterogeneity, the treatment of this malignancy is challenging. To date, liver biopsy and ultrasound (US) are the gold standard procedures for HCC diagnosis and surveillance, although they are not suitable for mass screening. Therefore, it is impelling to find new, less invasive diagnostic strategies able to detect HCC at an early stage as well as monitor tumor progression and recurrence. Common and rare inherited variations that boost the switching from NASH to liver cancer may help to predict tumor onset. Furthermore, epigenetic changes which reflect intertumoral heterogeneity occur early in tumorigenesis and are highly stable under pathologic conditions. The severity of hepatic injuries can be detected through the analysis of cell circulating tumor DNAs (ctDNAs), microRNAs (miRNAs), and noncoding RNAs (ncRNAs), which are involved in several pathological processes that feature cancer, including cell growth, survival, and differentiation, thus representing appealing biomarkers for HCC. Therefore, this review discusses the current options for HCC surveillance, focusing on the role of genetic and epigenetic biomarkers as new strategies to refine HCC management.

Keywords

NAFLD-HCC screening / genetic biomarkers / ncRNAs / epigenetics / early HCC detection

References

[1] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[2] Genome Atlas Network. Comprehensive molecular portraits of human breast tumours.Nature2012;490:61-70 PMCID:PMC3465532

[3] Day CP.From fat to inflammation.Gastroenterology2006;130:207-10

[4] Huang DQ,Loomba R.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2021;18:223-38 PMCID:PMC8016738

[5] Mittal S,Sada YH.Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2016;14:124-31.e1 PMCID:PMC4690789

[6] Dongiovanni P,Longo M,Fracanzani AL.Genetics, immunity and nutrition boost the switching from NASH to HCC.Biomedicines2021;9:1524 PMCID:PMC8614742

[7] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[8] Zhang H,Jiang L.Recent advances in systemic therapy for hepatocellular carcinoma.Biomark Res2022;10:3 PMCID:PMC8744248

[9] Tabacelia D,Dumitru R et al.New approach for hepatocellular carcinoma treatment.J Med Life2022;15:138-43

[10] Meroni M,Tria G.Genetics is of the essence to face NAFLD.Biomedicines2021;9:1359 PMCID:PMC8533437

[11] Valenti L.Mutant PNPLA3 I148M protein as pharmacological target for liver disease.Hepatology2017;66:1026-8

[12] Bruschi FV,Tardelli M.The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.Hepatology2017;65:1875-90

[13] Dongiovanni P,Fares R.PNPLA3 I148M polymorphism and progressive liver disease.World J Gastroenterol2013;19:6969-78 PMCID:PMC3819533

[14] Kozlitina J,Stender S.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2014;46:352-6 PMCID:PMC3969786

[15] Dongiovanni P,Maglio C.Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology2015;61:506-14

[16] Liu YL,Burt AD.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Nat Commun2014;5:4309 PMCID:PMC4279183

[17] Grandone A,Marzuillo P.TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.Pediatr Obes2016;11:115-9

[18] Goffredo M,Feldstein AE.Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: a multiethnic study.Hepatology2016;63:117-25 PMCID:PMC4688225

[19] Mancina RM,Incani M.Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children.Dig Liver Dis2016;48:100-1

[20] Donati B,Romeo S.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Sci Rep2017;7:4492 PMCID:PMC5495751

[21] Mancina RM,Petta S.The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent.Gastroenterology2016;150:1219-1230.e6 PMCID:PMC4844071

[22] Luukkonen PK,Hyötyläinen T.The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.J Hepatol2016;65:1263-5

[23] Meroni M,Fracanzani AL.MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD.EBioMedicine2020;57:102866 PMCID:PMC7339032

[24] Meroni M,Longo M.Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.EBioMedicine2020;52:102658 PMCID:PMC7026742

[25] Yang J,Nahon P.A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease.Hepatology2019;70:231-40

[26] Ki Kim S,Hatano E.TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.Int J Cancer2016;139:2512-8

[27] Buch S,Lutz PL.Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study .Gut2022;gutjnl-2022-327196:

[28] Donati B,Pingitore P.Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.Cancer Med2017;6:1930-40 PMCID:PMC5548883

[29] Petersen KF,Hariri A.Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.N Engl J Med2010;362:1082-9 PMCID:PMC2976042

[30] Pelusi S,Pietrelli A.Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease.Sci Rep2019;9:3682 PMCID:PMC6403344

[31] Meroni M,Paolini E.The rs599839 A>G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients.Cancers (Basel)2021;13:1783 PMCID:PMC8068289

[32] Dongiovanni P,Petta S.Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD.Biochim Biophys Acta Mol Cell Biol Lipids2020;1865:158765

[33] Lewis CM.Polygenic risk scores: from research tools to clinical instruments.Genome Med2020;12:44 PMCID:PMC7236300

[34] Dongiovanni P,Pietrelli A.Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.J Intern Med2018;283:356-70 PMCID:PMC5900872

[35] Bianco C,Pelusi S.Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol2021;74:775-82 PMCID:PMC7987554

[36] Di Costanzo A,Chiesa C.Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity.Pediatr Res2019;85:671-7 PMCID:PMC6760560

[37] Suomela E,Pitkänen N.Childhood predictors of adult fatty liver. The cardiovascular risk in young Finns Study.J Hepatol2016;65:784-90

[38] Xu M,Zhang S,Shen J.Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.Ann Hepatol2019;18:456-60

[39] Koo BK,Kim D.Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2020;18:2592-2599.e10

[40] Gellert-Kristensen H,Davey Smith G,Tybjaerg-Hansen A.Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population.Hepatology2020;72:845-56

[41] Longo M,Paolini E.TM6SF2/PNPLA3/MBOAT7 Loss-of-function genetic variants impact on nafld development and progression both in patients and in in vitro models.Cell Mol Gastroenterol Hepatol2022;13:759-88 PMCID:PMC8783129

[42] Hwang A,Zhu E.Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.PLoS One2018;13:e0198937 PMCID:PMC6019748

[43] Lim TS,Kim GM.Alpha-fetoprotein, des-gamma-carboxy prothrombin, and modified recist response as predictors of survival after transarterial radioembolization for hepatocellular carcinoma.J Vasc Interv Radiol2019;30:1194-1200.e1

[44] Rojas Á,Gil-gómez A.Performance of different biomarkers for the management of hepatocellular carcinoma.HR2018;4:31

[45] Pan Y,Yu J.Biomarkers in hepatocellular carcinoma: current status and future perspectives.Biomedicines2020;8:576 PMCID:PMC7762241

[46] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases.Hepatology2018;68:723-50

[47] Di Bisceglie AM,Chung RT.; HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial.J Hepatol2005;43:434-41

[48] Yang JD,Singal AG.Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase.Cancer Epidemiol Biomarkers Prev2017;26:1085-92 PMCID:PMC5519351

[49] Association for the Study of the Liver. Electronic address: [e-mail]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[50] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[51] Lok AS,Everhart JE.HALT-C Trial GroupDes-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Gastroenterology2010;138:493-502 PMCID:PMC2819612

[52] Tzartzeva K,Rich NE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-1718.e1 PMCID:PMC5927818

[53] Zhou JM,Zhang KH.AFP-L3 for the diagnosis of early hepatocellular carcinoma: a meta-analysis.Medicine (Baltimore)2021;100:e27673 PMCID:PMC8556013

[54] Nakamura S,Sakaguchi K.Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.Am J Gastroenterol2006;101:2038-43

[55] Lee S,Kim YS,Song KD.Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.Liver Int2016;36:580-7

[56] Best J,Sowa JP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-735.e4

[57] Zheng X,Lei Y,Liu M.Glypican-3: a novel and promising target for the treatment of hepatocellular carcinoma.Front Oncol2022;12:824208 PMCID:PMC8889910

[58] Huang TS,Turner R,Chen PJ.Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.Syst Rev2013;2:37 PMCID:PMC3682912

[59] Liu X,Zhang K.Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.Carcinogenesis2015;36:232-42

[60] Sun B,Wang B.Significance of glypican-3 (GPC3) expression in hepatocellular cancer diagnosis.Med Sci Monit2017;23:850-5 PMCID:PMC5325041

[61] Abou-Alfa GK,Daniele B.Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.J Hepatol2016;65:289-95

[62] Liu X,Jiang L.32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.J Transl Med2020;18:295 PMCID:PMC7398316

[63] Wu X,Shi B.Combined antitumor effects of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular carcinoma.Mol Ther2019;27:1483-94 PMCID:PMC6697347

[64] Chen D,Hong J.The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.Ann Surg Oncol2012;19:3556-65

[65] He XQ,Yu JJ.High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway.Tumour Biol2017;39:1010428317695971

[66] Saha SK,Yang GM.GPR50 promotes hepatocellular carcinoma progression via the notch signaling pathway through direct interaction with ADAM17.Mol Ther Oncolytics2020;17:332-49 PMCID:PMC7210388

[67] Kim SG,Yang YM.Molecular network of HCC aggressiveness.Oncoscience2015;2:777-8 PMCID:PMC4671915

[68] Lombardi R,Dongiovanni P,Fargion S.PD-1/PD-L1 immuno-mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease.Int J Mol Sci2022;23:2707 PMCID:PMC8910930

[69] Gok Yavuz B,Lee SS.Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma.J Hepatocell Carcinoma2021;8:1195-207 PMCID:PMC8478438

[70] Pinter M,Duda DG.The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review.JAMA Oncol2021;7:113-23 PMCID:PMC8265820

[71] Krummel MF.CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.J Exp Med1996;183:2533-40 PMCID:PMC2192613

[72] Sangro B,Wadhawan S.Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.J Hepatol2020;73:1460-9 PMCID:PMC7751218

[73] Duffy AG,Makorova-Rusher O.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol2017;66:545-51 PMCID:PMC5316490

[74] Feun LG,Wu C.Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.Cancer2019;125:3603-14 PMCID:PMC7592647

[75] Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma.Gut2020;69:2025-34

[76] Dongiovanni P,Longo M,Fracanzani AL.miRNA signature in NAFLD: a turning point for a non-invasive diagnosis.Int J Mol Sci2018;19:3966 PMCID:PMC6320931

[77] Pirola CJ,Burgueño AL.Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease.Gut2013;62:1356-63

[78] Kuramoto J,Tian Y.Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.Carcinogenesis2017;38:261-70 PMCID:PMC5862314

[79] Tian Y,Wong GL.Histone Deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma.Cancer Res2015;75:4803-16

[80] Crowley E,Loupakis F.Liquid biopsy: monitoring cancer-genetics in the blood.Nat Rev Clin Oncol2013;10:472-84

[81] Underhill HR,Hellwig S.Fragment length of circulating tumor DNA.PLoS Genet2016;12:e1006162 PMCID:PMC4948782

[82] Chan KC,Mok TS.Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.Clin Chem2008;54:1528-36

[83] Chan KC,Zheng YW.Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.Clin Chem2013;59:211-24

[84] Pessoa LS,Ferrer VP.ctDNA as a cancer biomarker: a broad overview.Crit Rev Oncol Hematol2020;155:103109

[85] Cao SQ,Sun BC.Long non-coding RNA highly up-regulated in liver cancer promotes exosome secretion.World J Gastroenterol2019;25:5283-99 PMCID:PMC6761235

[86] Klingenberg M,Diederichs S.Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets.J Hepatol2017;67:603-18

[87] Huang Z,Peng Y,Huang C.The role of long noncoding RNAs in hepatocellular carcinoma.Mol Cancer2020;19:77 PMCID:PMC7161154

[88] Stroun M,Lederrey C,Anker P.About the possible origin and mechanism of circulating DNA.Clinica Chimica Acta2001;313:139-42

[89] Mezzalira S,Guardascione M,Cecchin E.Circulating-free DNA analysis in hepatocellular carcinoma: a promising strategy to improve patients' management and therapy outcomes.Int J Mol Sci2019;20:5498 PMCID:PMC6861910

[90] Ye Q,Zheng S.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.Mol Cancer2019;18:114 PMCID:PMC6607541

[91] Xu RH,Krawczyk M.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.Nat Mater2017;16:1155-61

[92] Huang Z,Hu Y.Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma.Pathol Oncol Res2012;18:271-6

[93] Bratman SV,Iafolla MAJ.Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.Nat Cancer2020;1:873-81

[94] Rizzo A.Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.Cancer Treat Res Commun2021;27:100328

[95] Hsu C,Abbas A.Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC).JCO2020;38:3531-3531

[96] Goodman AM,Bazhenova L.Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers.Mol Cancer Ther2017;16:2598-608 PMCID:PMC5670009

[97] Harding JJ,Armenia J.Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies.Clin Cancer Res2019;25:2116-26 PMCID:PMC6689131

[98] Ling H,Calin GA.MicroRNAs and other non-coding RNAs as targets for anticancer drug development.Nat Rev Drug Discov2013;12:847-65 PMCID:PMC4548803

[99] Peng Y.The role of MicroRNAs in human cancer.Signal Transduct Target Ther2016;1:15004 PMCID:PMC5661652

[100] Fang Z,Wang L.MicroRNAs in the pathogenesis of nonalcoholic fatty liver disease.Int J Biol Sci2021;17:1851-63 PMCID:PMC8120467

[101] Lou G,Wu S.The p53/miR-34a/SIRT1 positive feedback loop in quercetin-induced apoptosis.Cell Physiol Biochem2015;35:2192-202

[102] Oura K,Masaki T.Molecular and functional roles of micrornas in the progression of hepatocellular carcinoma-a review.Int J Mol Sci2020;21:8362 PMCID:PMC7664704

[103] IIott NE,Roux B.Long non-coding RNAs and enhancer RNAs regulate the lipopolysaccharide-induced inflammatory response in human monocytes.Nat Commun2014;5:3979 PMCID:PMC4061460

[104] Huang R,Fan J,Wang B.Role of noncoding RNA in development of nonalcoholic fatty liver disease.Biomed Res Int2019;2019:8690592 PMCID:PMC6413411

[105] Leti F,Still CD.Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells.Transl Res2017;190:25-39.e21 PMCID:PMC5705449

[106] Yu F,Cai J.MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis.Cell Cycle2015;14:3885-96 PMCID:PMC4825734

[107] Yan C,Chen N.Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability.Sci Rep2016;6:22640 PMCID:PMC4776244

[108] Meroni M,Erconi V.mir-101-3p downregulation promotes fibrogenesis by facilitating hepatic stellate cell transdifferentiation during insulin resistance.Nutrients2019;11:2597 PMCID:PMC6893471

[109] Panzitt K,Guelly C.Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.Gastroenterology2007;132:330-42

[110] Zhang H,Liu F.Long noncoding RNA HULC promotes hepatocellular carcinoma progression.Aging (Albany NY)2019;11:9111-27 PMCID:PMC6834430

[111] Jin SS,Lin XF,Guan HQ.Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway.Ann Hepatol2022;27:100584

[112] Li W,Lin M.Up-regulated HOTAIR induced by fatty acids inhibits PTEN expression and increases triglycerides accumulation in HepG2 cells.2017;61:1412794

[113] Guo B,Yao L.LncRNA HOTAIR regulates the lipid accumulation in non-alcoholic fatty liver disease via miR-130b-3p/ROCK1 axis.Cell Signal2022;90:110190

[114] Schultheiss CS,Czepukojc B.The long non-coding RNA H19 suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma.Cell Stress2017;1:37-54 PMCID:PMC6551655

[115] Chen LL.Regulation of circRNA biogenesis.RNA Biol2015;12:381-8 PMCID:PMC4615371

[116] Zhao X,Xu J.Circular RNAs: biogenesis, mechanism, and function in human cancers.Int J Mol Sci2019;20:3926 PMCID:PMC6720291

[117] Zhang Y.Circular RNAs in hepatocellular carcinoma: emerging functions to clinical significances.Front Oncol2021;11:667428 PMCID:PMC8160296

[118] Guo XY,Sun F,Pan Q.circRNA_0046367 Prevents hepatoxicity of lipid peroxidation: an inhibitory role against hepatic steatosis.Oxid Med Cell Longev2017;2017:3960197 PMCID:PMC5605923

[119] Guo XY,Chen JN,Pan Q.circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.World J Gastroenterol2018;24:323-37 PMCID:PMC5776394

[120] Finck BN,Chen Z.Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway.Cell Metab2006;4:199-210

[121] Guo XY,Wang YQ.Circular RNA profiling and bioinformatic modeling identify its regulatory role in hepatic steatosis.Biomed Res Int2017;2017:5936171 PMCID:PMC5499244

[122] Zhu L,Zhu Z.Thymosin-β4 mediates hepatic stellate cell activation by interfering with CircRNA-0067835/miR-155/FoxO3 signaling pathway.Cell Physiol Biochem2018;51:1389-98

[123] Sun J,Li L,Fu L.MicroRNA-9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1.Oncol Rep2017;37:1698-706

[124] Chen Y,Wu Z,Zhang L.Microarray profiling of circular RNAs and the potential regulatory role of has_circ_0071410 in the activated human hepatic stellate cell induced by irradiation.Gene2017;629:35-42

[125] Gong Y,Wu D.Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6.Cancer Cell Int2018;18:116 PMCID:PMC6090603

[126] Guan Z,Gao W.Circular RNA hsa_circ_0016788 regulates hepatocellular carcinoma tumorigenesis through miR-486/CDK4 pathway.J Cell Physiol2018;234:500-8

[127] Zhang H,Ge S.Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7.Oncogene2019;38:2844-59 PMCID:PMC6484761

[128] Sim HW.Hepatocellular carcinoma in the era of immunotherapy.Curr Probl Cancer2018;42:40-8

[129] Han TS,Cho HS.Epigenetic associations between LNCRNA/CIRCRNA and MIRNA in hepatocellular carcinoma.Cancers (Basel)2020;12:2622 PMCID:PMC7565033

[130] Wu Y,Ding H.GPC-3 in hepatocellular carcinoma: current perspectives.J Hepatocell Carcinoma2016;3:63-7 PMCID:PMC5108608